News

Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc, an…
Read More...

H. Lundbeck A/S (Lundbeck) has entered into an agreement with biotech company ImmunoBrain Checkpoint, Inc. (IBC) for the rights to IBC's groundbreaking research in the treatment of…
Read More...

Allergan announced that Allergan's wholly-owned subsidiary, Allergan Sales LLC agreed to acquire Keller Medical, Inc., a privately held medical device company and developer of the…
Read More...

AbbVie Inc said on Wednesday its oral rheumatoid arthritis drug succeeded in a late-stage study on patients who had not adequately responded to standard treatments. The drug,…
Read More...

AstraZeneca announced that it has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of…
Read More...

Eli Lilly and Company and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of…
Read More...

Valeant Pharmaceuticals announced it has entered into an agreement to sell its iNova Pharmaceuticals ("iNova") business to a company jointly owned by funds advised and managed by…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company’s investigational treatment for transthyretin…
Read More...

Veloxis Pharmaceuticals A/S announced that its U.S. subsidiary, Veloxis Pharmaceuticals, Inc., has entered into an exclusive license, supply and distribution agreement with Chiesi…
Read More...

Novartis announced that the European Commission (EC) has approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna (nilotinib) Summary of Product Characteristics…
Read More...

A small study by researchers at the National Institutes of Health suggests that mutations in the gene CABLES1 may lead to Cushing syndrome, a rare disorder in which the body…
Read More...

Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as…
Read More...

Sanofi and Regeneron Pharmaceuticals announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1), in patients with…
Read More...

Braeburn Pharmaceuticals announced that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. A biopharmaceutical executive…
Read More...

ESSA Pharma, a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced that early data from the…
Read More...

Kamada, a plasma-derived protein therapeutics company focused on orphan indications, announced the appointment of Michal Stein, M.D., as Vice President and Medical Director for…
Read More...

BioCryst Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for a pediatric indication of…
Read More...

Cornerstone Pharmaceuticals announced that it is changing its corporate name to Rafael Pharmaceuticals effective immediately. The name change signifies a new era in the company’s…
Read More...

Aequus Pharmaceuticals and the Centre For Drug Research and Development (CDRD) announced a broad research collaboration to establish pre-clinical safety and efficacy of select…
Read More...

Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for  …
Read More...